1-3 of 3
outcome and assessment information set
Close
Sort by
Journal Articles

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Krimo Bouabdallah, MD, Guillaume Cartron, Rene-Olivier Casasnovas, MD, Noel-Jean Milpied, MD, Thomas Gastinne, MD, Andrew John Davies, PhD, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4158.
https://doi.org/10.1182/blood-2018-99-113777
Published: 2018
Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD
Journal: Blood
Blood (2016) 128 (22): 1096.
https://doi.org/10.1182/blood.V128.22.1096.1096
Published: 2016
Journal Articles

Glucose-6-Phosphate Dehydrogenase Deficiency in Saudi Arabia: A Survey

A. P. GELPI, M.D.
Journal: Blood
Blood (1965) 25 (4): 486–493.
https://doi.org/10.1182/blood.V25.4.486.486
Published: 1965